Figure 1 : Inhibition of (A) ABCB1-mediated rhodamine (Rh123) efflux in ABCB1-overexpressing SW620 Ad300 (left panel) and ABCB1-stably transfected HEK293 MDR1 cells (right panel) or (B) ABCG2-mediated pheophorbide a (PhA) efflux in ABCG2- overexpressing S1M1 80 cells (left panel) and ABCG2-stably transfected HEK293 ABCG2 cells (right panel) by volasertib.



Cells were incubated with 0.5 µg/mL Rh123 alone (black) (or 1 µM PhA alone), 0.5 µg/mL Rh123 with 1 µM PSC833 (a ABCB1-specific inhibitor) (red) (or 1 µM PhA with 10 µM FTC (a ABCG2-specific inhibitor), or 0.5 µg/mL Rh123 (or 1 µM PhA) with volasertib at the indicated concentrations (0.25, 0.5, 1, or 2 µM) (in various different colors as indicated) at 37°C for 30 min. Rh123 or PhA fluorescence retention in the cells after 1-h fluorescent substrate-free efflux was measured by flow cytometry. Representative histograms from at least three independent experiments are shown.

To et al.Journal of Cancer Therapeutics and Research  2013 2:13DOI : 10.7243/2049-7962-2-13